On this page you will find our recommendations sorted by BNF chapter.
Appraisal Reports are available to stakeholders on request.
Where a decision is >24 months old; these are highlighted in red. If you are a clinician working within the NTAG region and would like to prioritise an old decision for re-review please contact the professional secretary on firstname.lastname@example.org
|Budesonide orodispersible for maintenance treatment of eosinophilic oesophagitis||Recommendation||Recommended as an option||07/06/2022|
|Infliximab biosimilars||See Musculoskeletal and joint diseases recommendations||Recommended as an option||02/06/2015|
|Infliximab Subcutaneous (Remsima®)||Musculoskeletal and joint diseases recommendations||Recommended as an option during Covid-19 Pandemic.||22/02/2022|
|Leukapheresis with Adacolumn™ for Inflammatory Bowel Disease (NETAG)||Recommendation||Not recommended||18/01/2011|
|Transanal Irrigation Systems (TAIs) for neurogenic bowel dysfunction, chronic constipation, and chronic faecal incontinence||Recommended for restricted use. Recommended as per NTAG Decision Summary in NENC Medicines Committee Recommendations from December 2022 https://northeastnorthcumbria.nhs.uk/about-us/publications/medicines-committee/||15/11/2022|